Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 6/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | ACHE | P22303 | 6/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16272988 | 0.88 | TDP1 (0.51) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL28271381 | 0.87 | TDP1 (0.54) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL16124577 | 0.87 | CA12 (0.50) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL5265859 | 0.85 | NAAA (0.53) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL1710035 | 0.85 | CA12 (0.48) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL26947556 | 0.84 | TDP1 (0.67) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL14218312 | 0.83 | CA12 (0.47) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL27829380 | 0.83 | CA12 (0.47) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL13416735 | 0.83 | CA12 (0.47) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL18675948 | 0.82 | CA12 (0.46) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4119539-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-01-18 | — | — | EP | disclosed |
| EP-4119539-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-01-18 | — | — | EP | disclosed |
| EP-3353145-B1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPHARMA LTD (KY) | 2022-09-28 | — | — | EP | disclosed |
| CN-113061089-A | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-07-02 | — | — | CN | disclosed |
| WO-2021127461-A1 | METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID | XW LABORATORIES LIMITED (CN) | 2021-06-24 | — | — | WO | disclosed |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-05-06 | — | — | US | disclosed |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-05-06 | — | — | US | disclosed |
| CN-108283000-B | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10941107-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2021-03-09 | — | — | US | disclosed |
| US-10941107-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2021-03-09 | — | — | US | disclosed |
| US-10457627-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2019-10-29 | — | — | US | disclosed |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-07-18 | — | — | US | disclosed |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-07-18 | — | — | US | disclosed |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-06-27 | — | — | US | disclosed |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-06-27 | — | — | US | disclosed |
| WO-2017050259-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017049470-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (CN) | 2017-03-30 | — | — | WO | disclosed |
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2250164-A2 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | Nicox S.A. (FR) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009106471-A2 | NEW ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | NICOX S.A. (FR) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941107-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB2, GABRB3, GABRB1 | TDP1 2906/4885CA12 2144/4885CA1 1258/4885 |
| US-10457627-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | TDP1 2265/4885CA12 1923/4885CA1 1450/4885 |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | TDP1 2265/4885CA12 1923/4885CA1 1450/4885 |
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | AGTR1, AGTR2, AGT | TDP1 4548/4885CA12 4398/4885CA1 4707/4885 |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB2, GABRB3, GABRB1 | TDP1 2906/4885CA12 2144/4885CA1 1258/4885 |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | TDP1 2265/4885CA12 1923/4885CA1 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.